The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
|Articles|March 2, 2014
- Pharmaceutical Technology-03-02-2014
- Volume 38
- Issue 3
Pharmaceutical Technology, March 2014 Issue (PDF)
Click the title above to open the Pharmaceutical Technology March 2014 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 12 years ago
Under New Ownershipover 12 years ago
Current issues with nanomedicinesover 12 years ago
Optimizing Solid Dosage Manufacturingover 12 years ago
European Union Packaging Safety Features Come into Effectover 12 years ago
Comparing Drug Layering and Direct Pelletization Processesover 12 years ago
7900 ICP-MS Increases Efficiencyover 12 years ago
Regulators Get Tough on Corruption in Chinaover 12 years ago
Best Practices in Adopting Single-Use Systemsover 12 years ago
Manufacturers Struggle with Breakthrough Drug DevelopmentAdvertisement
Related to this article
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Advertisement
Advertisement